Publication | Closed Access

Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: Results from an open-label extension study for patients from REVEAL

Open-label Extension StudyLong-term EfficacyMedicineSevere PsoriasisClinical DermatologyDermatologyPsoriatic Arthritis